164 related articles for article (PubMed ID: 38509231)
1. E-cadherin interacts with EGFR resulting in hyper-activation of ERK in multiple models of breast cancer.
Russo GC; Crawford AJ; Clark D; Cui J; Carney R; Karl MN; Su B; Starich B; Lih TS; Kamat P; Zhang Q; Nair PR; Wu PH; Lee MH; Leong HS; Zhang H; Rebecca VW; Wirtz D
Oncogene; 2024 May; 43(19):1445-1462. PubMed ID: 38509231
[TBL] [Abstract][Full Text] [Related]
2. Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer.
Bae GY; Choi SJ; Lee JS; Jo J; Lee J; Kim J; Cha HJ
Oncotarget; 2013 Dec; 4(12):2512-22. PubMed ID: 24318272
[TBL] [Abstract][Full Text] [Related]
3. Epithelial requirement for in vitro proliferation and xenograft growth and metastasis of MDA-MB-468 human breast cancer cells: oncogenic rather than tumor-suppressive role of E-cadherin.
Hugo HJ; Gunasinghe NPAD; Hollier BG; Tanaka T; Blick T; Toh A; Hill P; Gilles C; Waltham M; Thompson EW
Breast Cancer Res; 2017 Jul; 19(1):86. PubMed ID: 28750639
[TBL] [Abstract][Full Text] [Related]
4. TMEM52B suppression promotes cancer cell survival and invasion through modulating E-cadherin stability and EGFR activity.
Lee Y; Ko D; Yoon J; Lee Y; Kim S
J Exp Clin Cancer Res; 2021 Mar; 40(1):58. PubMed ID: 33641663
[TBL] [Abstract][Full Text] [Related]
5. FGFR3 promotes the growth and malignancy of melanoma by influencing EMT and the phosphorylation of ERK, AKT, and EGFR.
Li L; Zhang S; Li H; Chou H
BMC Cancer; 2019 Oct; 19(1):963. PubMed ID: 31619201
[TBL] [Abstract][Full Text] [Related]
6. A Ca
Dang DK; Makena MR; Llongueras JP; Prasad H; Ko M; Bandral M; Rao R
Mol Cancer Res; 2019 Aug; 17(8):1735-1747. PubMed ID: 31076498
[TBL] [Abstract][Full Text] [Related]
7. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin.
Zuo JH; Zhu W; Li MY; Li XH; Yi H; Zeng GQ; Wan XX; He QY; Li JH; Qu JQ; Chen Y; Xiao ZQ
J Cell Biochem; 2011 Sep; 112(9):2508-17. PubMed ID: 21557297
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-Resistant TNBC Cells Exhibit Rapid Growth with Cancer Stem Cell-like Properties and EMT Phenotype, Which Can Be Transferred to Parental Cells through Autocrine Signaling.
Paramanantham A; Jung EJ; Kim HJ; Jeong BK; Jung JM; Kim GS; Chan HS; Lee WS
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830320
[TBL] [Abstract][Full Text] [Related]
9. The paradox of E-cadherin: role in response to hypoxia in the tumor microenvironment and regulation of energy metabolism.
Chu K; Boley KM; Moraes R; Barsky SH; Robertson FM
Oncotarget; 2013 Mar; 4(3):446-62. PubMed ID: 23530113
[TBL] [Abstract][Full Text] [Related]
10. Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells.
Wu Y; Ginther C; Kim J; Mosher N; Chung S; Slamon D; Vadgama JV
Mol Cancer Res; 2012 Dec; 10(12):1597-606. PubMed ID: 23071104
[TBL] [Abstract][Full Text] [Related]
11. CD147 promotes breast cancer migration and invasion by inducing epithelial-mesenchymal transition via the MAPK/ERK signaling pathway.
Li F; Wang J; Yan YQ; Bai CZ; Guo JQ
BMC Cancer; 2023 Dec; 23(1):1214. PubMed ID: 38066486
[TBL] [Abstract][Full Text] [Related]
12. Glypican-3 induces a mesenchymal to epithelial transition in human breast cancer cells.
Castillo LF; Tascón R; Lago Huvelle MR; Novack G; Llorens MC; Dos Santos AF; Shortrede J; Cabanillas AM; Bal de Kier Joffé E; Labriola L; Peters MG
Oncotarget; 2016 Sep; 7(37):60133-60154. PubMed ID: 27507057
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of epithelial to mesenchymal transition by E-cadherin up-regulation via repression of slug transcription and inhibition of E-cadherin degradation: dual role of scaffold/matrix attachment region-binding protein 1 (SMAR1) in breast cancer cells.
Adhikary A; Chakraborty S; Mazumdar M; Ghosh S; Mukherjee S; Manna A; Mohanty S; Nakka KK; Joshi S; De A; Chattopadhyay S; Sa G; Das T
J Biol Chem; 2014 Sep; 289(37):25431-44. PubMed ID: 25086032
[TBL] [Abstract][Full Text] [Related]
14. Metformin mediated reversal of epithelial to mesenchymal transition is triggered by epigenetic changes in E-cadherin promoter.
Banerjee P; Surendran H; Chowdhury DR; Prabhakar K; Pal R
J Mol Med (Berl); 2016 Dec; 94(12):1397-1409. PubMed ID: 27534967
[TBL] [Abstract][Full Text] [Related]
15. The Cdc42/Rac1 regulator CdGAP is a novel E-cadherin transcriptional co-repressor with Zeb2 in breast cancer.
He Y; Northey JJ; Pelletier A; Kos Z; Meunier L; Haibe-Kains B; Mes-Masson AM; Côté JF; Siegel PM; Lamarche-Vane N
Oncogene; 2017 Jun; 36(24):3490-3503. PubMed ID: 28135249
[TBL] [Abstract][Full Text] [Related]
16. ERbeta1 represses basal breast cancer epithelial to mesenchymal transition by destabilizing EGFR.
Thomas C; Rajapaksa G; Nikolos F; Hao R; Katchy A; McCollum CW; Bondesson M; Quinlan P; Thompson A; Krishnamurthy S; Esteva FJ; Gustafsson JÅ
Breast Cancer Res; 2012 Nov; 14(6):R148. PubMed ID: 23158001
[TBL] [Abstract][Full Text] [Related]
17. Med19 is targeted by miR-101-3p/miR-422a and promotes breast cancer progression by regulating the EGFR/MEK/ERK signaling pathway.
Zhang X; Gao D; Fang K; Guo Z; Li L
Cancer Lett; 2019 Mar; 444():105-115. PubMed ID: 30583076
[TBL] [Abstract][Full Text] [Related]
18. N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties.
Qian X; Anzovino A; Kim S; Suyama K; Yao J; Hulit J; Agiostratidou G; Chandiramani N; McDaid HM; Nagi C; Cohen HW; Phillips GR; Norton L; Hazan RB
Oncogene; 2014 Jun; 33(26):3411-21. PubMed ID: 23975425
[TBL] [Abstract][Full Text] [Related]
19. Nuclear factor I-C regulates E-cadherin via control of KLF4 in breast cancer.
Lee HK; Lee DS; Park JC
BMC Cancer; 2015 Mar; 15():113. PubMed ID: 25879941
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin.
Shah P; Gau Y; Sabnis G
Breast Cancer Res Treat; 2014 Jan; 143(1):99-111. PubMed ID: 24305977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
